Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 86
- Registration Number
- NCT00521521
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
- Conditions
- Neoplasm MetastasisProstatic Neoplasms
- Interventions
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1224
- Registration Number
- NCT00519285
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT00518427
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 413
- Registration Number
- NCT00514917
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina
- Conditions
- Hypertension
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2009-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 271
- Registration Number
- NCT00507845
- Locations
- 🇦🇷
Sanofi-aventis administrative office, Buenos Aires, Argentina
Dose-effect of SSR180575 in Diabetic Neuropathy
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 309
- Registration Number
- NCT00502515
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
- Conditions
- Liver CirrhosisAscites
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2007-07-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT00501566
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
- Conditions
- AscitesLiver Cirrhosis
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2009-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 110
- Registration Number
- NCT00501722
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Satavaptan Dose-Ranging Study in the Prevention of Ascites
- Conditions
- AscitesLiver Cirrhosis
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2009-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 151
- Registration Number
- NCT00501384
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1617
- Registration Number
- NCT00500604
- Locations
- 🇻🇳
Sanofi-Aventis Administrative Office, Ho Chi Minh City, Vietnam